AXR-159 is under clinical development by AxeroVision and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AXR-159’s likelihood of approval (LoA) and phase transition for Keratoconjunctivitis Sicca (Dry Eye) took place on 21 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AXR-159 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AXR-159 (GW559090) is under development for dry eye (keratoconjunctivitis sicca) syndrome. The drug candidate is administered through ophthalmic and inhalation routes. It tagets single peptidic alpha4beta1 (VLA-4) protein.
It was also under development for the treatment of asthma, allergic rhinitis and upper respiratory inflammatory disease (URID).
AxeroVision is a biotechnology company which develops therapeutics for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases. The company is investigating AXR-159, a VLA-4 integrin antagonist for the treatment of moderate and severe dry eye disease. It is funded by Laboratories Thea and GlaxoSmithKline Plc (GSK). The company is a spin off from GlaxoSmithKline Plc. AxeroVision is headquartered in Carlsbad, California, the US.
Quick View AXR-159 LOA Data
|Highest Development Stage|